Study guide
6.5 The Bishop Score & Cervical Ripening Methods
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
6.5 The Bishop Score & Cervical Ripening Methods
Key Takeaways Explain This Topic AI
A Bishop score of 8 or more predicts vaginal birth rates comparable to spontaneous labor, while a score below 6 defines an unfavorable cervix requiring ripening.
The transcervical Foley catheter inflated with 30 to 60 mL carries a negligible risk of tachysystole and is the first-line ripening method in trial of labor after cesarean.
Misoprostol and dinoprostone are absolutely contraindicated with a prior cesarean or transmural uterine surgery because of catastrophic uterine rupture risk.
Vaginal misoprostol is dosed at 25 mcg every 3 to 6 hours, and oxytocin must be delayed at least 4 hours after the last dose.
The dinoprostone vaginal insert releases about 0.3 mg per hour over 12 hours and can be removed by its retrieval string if tachysystole occurs, with oxytocin started 30 to 60 minutes after removal.
Last updated: September 2026
Pre-Induction Cervical Assessment: The Bishop Score
The Bishop score is a standardized clinical scoring tool used to predict the likelihood of successful vaginal delivery following induction. An unfavorable cervix is associated with prolonged latent phases, higher rates of failed induction, and increased cesarean birth.
The Standardized Bishop Scoring System
- Clinical Parameter Score = 0 Score = 1 Score = 2 Score = 3
- Cervical Dilation (cm) Closed (0 cm) 1–2 cm 3–4 cm ≥ 5 cm
- Cervical Effacement (%) 0%–30% 40%–50% 60%–70% ≥ 80%
- Fetal Station (–3 to +3) –3 –2 –1 / 0 +1 / +2
- Cervical Consistency Firm Medium Soft —
- Cervical Position Posterior Midposition Anterior —
- Clinical Interpretation & Decision-Making
Bishop Score ≥ 8: Indicates a "ripe" or favorable cervix. The probability of achieving a successful vaginal birth with oxytocin induction alone is comparable to that of spontaneous labor onset. Cervical ripening agents are not required.
Bishop Score < 6: Indicates an "unripe" or unfavorable cervix. Attempting direct oxytocin induction without prior cervical ripening results in high failure rates and increased cesarean deliveries. Pre-induction cervical ripening is clinically indicated.
Bishop Score 6–7: Intermediate. The clinician may consider ripening or direct oxytocin depending on parity, membranes status, and clinical urgency.
Mechanical Methods of Cervical Ripening
Mechanical ripening methods act by directly dilating the endocervical canal and causing mechanical separation (stripping) of the amnion and chorion from the lower uterine segment, which stimulates local decidual release of endogenous prostaglandin F2α (PGF2α) and prostaglandin E2 (PGE2) . Mechanical stretching also activates the neuroendocrine Ferguson reflex , stimulating neurohypophyseal oxytocin release.
Transcervical Foley Bulb Catheter
Technique: A 16-Fr to 18-Fr Foley urinary catheter with a 30-mL balloon is inserted through the internal cervical os under direct visualization (speculum) or digitally. Once past the internal os, the balloon is inflated with 30 to 60 mL of sterile water or normal saline . The catheter is then taped to the inner aspect of the maternal thigh with gentle tension. Alternatively, a double-balloon catheter (Cook cervical ripening balloon) can be used, with 80 mL instilled into both the uterine and vaginal balloons.
Clinical Trajectory: The catheter remains in place until it spontaneously expels (which signifies that the cervix has dilated to approximately 3 cm, usually within 6 to 12 hours) or for a maximum of 12 to 24 hours.
Safety & TOLAC Profile: Unlike pharmacologic agents, mechanical catheters carry a negligible risk of uterine tachysystole or hyperstimulation with associated fetal heart rate decelerations. Consequently, the transcervical Foley bulb is the preferred first-line ripening method for Trial of Labor After Cesarean (TOLAC) / Vaginal Birth After Cesarean (VBAC) .
Contraindications: Low-lying placenta, unexplained vaginal bleeding, ruptured membranes with active intraamniotic infection, or cervical anatomical abnormalities.
Hygroscopic Dilators
Laminaria digitata (dried seaweed stems) or synthetic hydrophilic polymers ( Dilapan-S ). They absorb endocervical moisture, expanding radially to slowly dilate the cervix. Primarily utilized in second-trimester terminations or late fetal demise, and less commonly in modern term labor induction.
Pharmacologic Cervical Ripening Agents
Exogenous prostaglandins act on cervical connective tissue by dissolving collagen fibrils, altering glycosaminoglycan composition, increasing submucosal water content, and relaxing cervical smooth muscle, while simultaneously stimulating myometrial contractility.
Prostaglandin E1: Misoprostol (Cytotec)
Misoprostol is a synthetic methyl ester analogue of prostaglandin E1. It is inexpensive, stable at ambient room temperature, and possesses rapid systemic absorption.
Intravaginal Dosing: 25 mcg (one-fourth of a 100-mcg tablet) placed in the posterior vaginal fornix every 3 to 6 hours . Doses should not exceed 25 mcg per administration; higher doses (e.g., 50 mcg) significantly increase the risk of uterine tachysystole without accelerating delivery time.
Oral Dosing: 25 to 50 mcg orally every 2 to 4 hours, or a titrated oral solution (20 to 25 mcg dissolved in water given every 2 hours). Oral administration produces fewer episodes of tachysystole with fetal heart rate decelerations than vaginal administration.
Oxytocin Timing: Oxytocin administration must be delayed for at least 4 hours following the last dose of misoprostol to prevent synergistic myometrial hyperstimulation.
CRITICAL BLACK-BOX CONTRAINDICATION: Misoprostol is ABSOLUTELY CONTRAINDICATED in patients with a prior cesarean delivery or prior transmural uterine surgery (e.g., full-thickness myomectomy). Its potent uterotonic effect carries an unacceptably high rate of catastrophic uterine rupture (5% to 10%+) in the scarred uterus.
Prostaglandin E2: Dinoprostone
Dinoprostone is a naturally occurring prostaglandin E2 formulation.
Vaginal Insert (Cervidil): A 10-mg dinoprostone reservoir contained within a knitted polyester retrieval system. It releases drug at a controlled rate of approximately 0.3 mg per hour over 12 hours . It is placed transversely in the posterior vaginal fornix.
Clinical Advantage: If uterine tachysystole or non-reassuring fetal heart rate tracings develop, the insert can be immediately removed via its retrieval string, leading to rapid cessation of drug delivery.
Oxytocin Timing: Oxytocin may be initiated 30 to 60 minutes after removal of the Cervidil insert.
Intracervical Gel (Prepidil): 0.5 mg dinoprostone in a 2.5-mL syringe administered through a catheter into the endocervical canal just below the internal os. May repeat every 6 hours to a maximum of 3 doses (1.5 mg) in 24 hours. Oxytocin must be delayed for 6 to 12 hours after the last gel dose. Prepidil cannot be easily retrieved if tachysystole occurs.
Contraindications: Like misoprostol, dinoprostone is contraindicated in patients with a scarred uterus (prior cesarean or transmural uterine surgery). It is also contraindicated in patients with active asthma, unexplained vaginal bleeding, or multiparity (≥ 6 previous term births).
Clinical Comparison of Ripening Modalities
- Feature Foley Bulb (Mechanical) Misoprostol / PGE1 Dinoprostone / PGE2 (Cervidil)
- Cost & Storage Very low cost; room temp Very low cost; room temp Moderate to high cost; requires refrigeration
- Risk of Tachysystole Negligible (nearly 0%) Higher (~5%–12%) Moderate (~2%–5%)
- Reversibility Immediate (deflate/remove) Irreversible once absorbed Rapidly reversible (pull string)
- Use in TOLAC / VBAC Safe; First-line choice STRICTLY CONTRAINDICATED STRICTLY CONTRAINDICATED
- Time to Oxytocin Immediately upon removal Delay ≥ 4 hours after last dose Delay 30–60 min after removal